How The Skin Disease Psoriasis Costs Us Billions

A patch of psoriasis on an elbow. iStockphoto hide caption

A patch of psoriasis on an elbow.

Skin disorders rarely make it on the list of big-time diseases, so when we saw a study saying that psoriasis costs the nation $52 to $63 billion a year, it was hard not to think, "Really?"

And that's just for the direct costs of health care for people with psoriasis, according to the study, published Wednesday in JAMA Dermatology.

Indirect costs such as lost work hours and unemployment make up another $24 to $35 billion, the study found. Then there are the costs of associated health problems like heart disease and depression, at $35 billion. That's a lot of money for something that could easily be dismissed as a rash by those of us who aren't up to speed on psoriasis. But as those numbers suggest, we'd be wrong.

Psoriasis is an autoimmune disease that affects about 3 percent of the population; its most obvious manifestation is thick red or scaly skin patches, caused by skin cells dividing too fast. About 10 to 20 percent of people also get an inflammatory type of arthritis, according to the Centers for Disease Control and Prevention. It's a chronic disease, and there's no medication that cures it. Treatments range from over-the-counter skin moisturizers to try to tame the cracking and scaling to ultraviolet light therapy, traditional systemic drugs like methotrexate, and newer biologic drugs that target parts of the immune system.

Bottom line: There are millions of people dealing with a chronic illness that can be disfiguring and disabling. To find out it's like to deal with psoriasis, we called Todd Bello, a 51-year-old from Stony Brook, N.Y. When he was diagnosed with psoriasis at age 28, he started going to the doctor several times a week and trying different treatments.

Bello worked as a letter carrier for the Postal Service, coached his children's soccer games and volunteered as a firefighter and EMT. The psoriasis made his skin crack and bleed when he got in and out of the postal truck. His feet swelled to the point that he couldn't wear shoes. Eventually had to retire on disability. "It's very frustrating for a person who needs to make a living," Bello told Shots. "I'm very fortunate and grateful that my wife has a great job and we're able to pay for the medication I need."

Bello volunteered for several clinical trials for experimental psoriasis drugs. One failed to help. Another, Raptiva, worked wonderfully, Bello says, but was taken off the market because it increased the risk of deadly brain infections. "I wasn't very happy at that point," he says.

He tried Enbrel, another biologic; didn't work. But a third, Stelara, banished symptoms for five years. "Unfortunately, it was temporary," Bello says.

Here is the original post:

How The Skin Disease Psoriasis Costs Us Billions

CU School of Medicine's April Armstrong estimates cost of psoriasis in the US

AURORA, Colo. (Jan. 7. 2015) - The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by JAMA Dermatology.

Psoriasis affects about 3.2 percent of the U.S. population and understanding the economic burden of the disease is important for research, advocacy and educational efforts.

April Armstrong, MD, MPH, associate professor and vice chair of clinical research in the Department of Dermatology at the University of Colorado School of Medicine, is the senior and corresponding author of the article. Armstrong, along with co-authors, reviewed 22 studies to estimate the direct, indirect, intangible and comorbidity costs of adult psoriasis. The results were adjusted to 2013 dollars.

Their review found direct psoriasis costs ranged from $51.7 billion to $63.2 billion, while indirect costs (due to absenteeism or going to work while sick) ranged from $23.9 billion to $35.4 billion. Medical comorbidities were estimated to contribute another $36.4 billion. And intangible costs (to eliminate the negative effects of psoriasis in physical and mental health) amounted to a one-time cost of up to $11,498 per patient with psoriasis, according to the review results.

"The direct health care costs are significantly greater for patients with psoriasis than for the general population and are also higher for patients with increasing psoriasis disease severity. ... Defining the economic burden of psoriasis from a societal perspective is the foundation for innovating and providing access to cost-effective therapies that will result in improved patient outcomes," the authors note.

The article is published online today.

###

About the University of Colorado School of Medicine

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Health, Children's Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical school's care, education, research and community engagement, visit its web site.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:

CU School of Medicine's April Armstrong estimates cost of psoriasis in the US

Review article estimates annual US cost of psoriasis in 2013

The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by JAMA Dermatology.

Psoriasis affects about 3.2 percent of the U.S. population and understanding the economic burden of the disease is important for research, advocacy and educational efforts.

Elizabeth A. Brezinski, M.D., of the University of California, Davis, Sacramento, and coauthors reviewed 22 studies to estimate the direct, indirect, intangible and comorbidity costs of adult psoriasis. The results were adjusted to 2013 dollars.

Their review found direct psoriasis costs ranged from $51.7 billion to $63.2 billion, while indirect costs (due to absenteeism or going to work while sick) ranged from $23.9 billion to $35.4 billion. Medical comorbidities were estimated to contribute another $36.4 billion. And intangible costs (to eliminate the negative effects of psoriasis in physical and mental health) amounted to a one-time cost of up to $11,498 per patient with psoriasis, according to the review results.

"The direct health care costs are significantly greater for patients with psoriasis than for the general population and are also higher for patients with increasing psoriasis disease severity. Defining the economic burden of psoriasis from a societal perspective is the foundation for innovating and providing access to cost-effective therapies that will result in improved patient outcomes," the authors note.

Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.

See the rest here:

Review article estimates annual US cost of psoriasis in 2013

US woman with psoriasis has patches of silver 'bark' forming over her body

WARNING: GRAPHIC CONTENT Pat Schuerman, 50, was diagnosed with skin condition psoriasis at age 24 Patches of thick, red welts and rough, silvery scales that look like bark or plaster of Paris are forming all over her body, leaving her feeling 'hideous' Has been thrown out of shops as owners worry her condition is contagious Developed psoriatic arthritis in her joints which makes walking difficult Now no longer leaves the house due to insecurities over her looks

By Madlen Davies for MailOnline

Published: 09:56 EST, 5 January 2015 | Updated: 17:37 EST, 5 January 2015

121 shares

74

View comments

Pat Schuerman, 50, says she no longer leaves the house because insecurities over her psoriasis have left her feeling 'hideous' and like a 'leper'

A woman has described how unsightly patches of silvery 'bark' are forming all over her body as a result of the skin condition psoriasis.

Pat Schuerman, 50, is covered in thick, red welts and rough, silvery scales, which she described as 'looking like bark' or 'plaster of Paris'.

She is constantly itching and feels 'hideous', but despite trying a range of treatments to help manage her condition, nothing has worked.

Continued here:

US woman with psoriasis has patches of silver 'bark' forming over her body

LEO Pharma submits NDA to US FDA for aerosol foam to treat plaque psoriasis

PBR Staff Writer Published 06 January 2015

LEO Pharma has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) seeking approval for calcipotriene and betamethasone dipropionate aerosol foam to treat patients with plaque psoriasis, the most common clinical form of psoriasis.

The aerosol foam formulation of the fixed combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, has been developed to improve treatment for patients with plaque psoriasis.

The NDA is based on studies of patients with plaque psoriasis, which include the Phase IIIa PSO-FAST trial that evaluated efficacy and safety at four weeks and the Phase II MUSE safety trial.

LEO Pharma president and CEO Barbara Osborne said: "Psoriasis is a chronic, debilitating disease. Patients with inadequately managed plaque psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancer.

"With the regulatory submission announced today, we are taking a step further towards providing additional topical treatment options for people living with psoriasis."

The company said that regulatory filings in Europe and other countries are planned during the course of 2015 and 2016.

See the rest here:

LEO Pharma submits NDA to US FDA for aerosol foam to treat plaque psoriasis

Healthline and National Psoriasis Foundation Partner for Social Media Initiative Aimed to Empower and Support …

San Francisco, CA (PRWEB) January 05, 2015

Healthline.com, a leading source of timely health information, news and resources, today announced it is partnering with the National Psoriasis Foundation (NPF), the worlds largest nonprofit serving millions of Americans with psoriatic disease, to launch a new social media initiative aimed at supporting and empowering those who are living with psoriasis. Psoriasis is the most prevalent autoimmune disease in the U.S., impacting as many as 7.5 million Americans.

Psoriatic disease has a profound impact on peoples emotional and physical well-being, and people with psoriasis often describe feeling lonely, isolated and embarrassed, said Noe Baker, public relations manager at the National Psoriasis Foundation. The more that people with psoriatic disease are able to connect with others through online and share experiences, the less isolating the disease can be. Social media helps many people with psoriatic disease realize that others know just what theyre going through.

People can participate in two ways:

It's imperative for psoriasis sufferers to know they are not alone, said Alisha Bridges, who has been dealing with psoriasis for 20 years. The biggest help in my coming out with this disease was meeting others who were conquering psoriasis and refusing to be ashamed. The You've Got This campaign is a great way to connect others through the use of social media.

We know from creating other support communities for HIV/AIDS, multiple sclerosis and bipolar disorder that people living with chronic illness really value hearing from those who are also affected by it. Insights from fellow community members can be extremely impactful, especially for those who are recently diagnosed and coming to terms with their new reality, said Tracy Rosecrans, VP of marketing for Healthline.com. Now, through Healthlines partnership with the NPF, the psoriasis community has its own place to share personal journeys and spread the message to others that they are not aloneand theyve got this.

About the National Psoriasis Foundation National Psoriasis Foundation (NPF) is the world's largest organization serving people with psoriasis and psoriatic arthritis. Our priority is to provide the information and services for people to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our patient and professional education and advocacy initiatives, NPF has funded more than $11 million in psoriatic disease research. Visit us online at http://www.psoriasis.org or call 800.723.9166. Follow NPF on Facebook and Twitter.

About Healthline Healthline provides intelligent health information and technology solutions that help healthcare organizations and everyday people make more informed healthcare decisions, improve outcomes and reduce costs. Powered by the worlds largest medical taxonomy platform, Healthlines Health Data Solutions, Health Engagement Solutions and Health Marketing Solutions leverage advanced concept-mapping technology to deliver accurate, actionable insights. Additionally, the companys consumer website, Healthline.com, delivers relevant, timely health information, news and resources to help consumers manage their health. Healthline is currently used by more than 25 million consumers per month and some of healthcares largest brands, including AARP, Aetna, UnitedHealth Group, Microsoft, IBM, GE and Elsevier. For more information, please visit corp.healthline.com and http://www.healthline.com, or follow @HealthlineCorp and @Healthline on Twitter.

Go here to read the rest:

Healthline and National Psoriasis Foundation Partner for Social Media Initiative Aimed to Empower and Support ...

Woman, 50, has huge patches of silver 'bark' forming all over her body due to 'hideous' skin condition psoriasis

WARNING: GRAPHIC CONTENT Pat Schuerman, 50, was diagnosed with skin condition psoriasis at age 24 Patches of thick, red welts and rough, silvery scales that look like bark or plaster of Paris are forming all over her body, leaving her feeling 'hideous' Has been thrown out of shops as owners worry her condition is contagious Developed psoriatic arthritis in her joints which makes walking difficult Now no longer leaves the house due to insecurities over her looks

By Madlen Davies for MailOnline

Published: 09:56 EST, 5 January 2015 | Updated: 15:31 EST, 5 January 2015

Pat Schuerman, 50, says she no longer leaves the house because insecurities over her psoriasis have left her feeling 'hideous' and like a 'leper'

A woman has described how unsightly patches of silvery 'bark' are forming all over her body as a result of the skin condition psoriasis.

Pat Schuerman, 50, is covered in thick, red welts and rough, silvery scales, which she described as 'looking like bark' or 'plaster of Paris'.

She is constantly itching and feels 'hideous', but despite trying a range of treatments to help manage her condition, nothing has worked.

She now no longer leaves the house due to her insecurities, and has also developed arthritis in her joints - a problem related to her skin condition - making walking painful.

Her insecurities grew after she was thrown out a library and swimming pool due to psoriasis, which also affects celebrities such as Kim Kardashian, LeAnne Rimes and The Only Way Is Essex's Jessica Wright.

'I was asked to leave our local library because people complained I was getting flakes on the keyboard,' Miss Schuerman from Arizona, U.S., said.

More:

Woman, 50, has huge patches of silver 'bark' forming all over her body due to 'hideous' skin condition psoriasis

Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Illinois, Chicago – Video


Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Illinois, Chicago
Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Healing From Deadly Diseases, Real Healer and Real Results of His Treatment, Mujin Troi The path to the miracle...

By: The SunGates Center

See the original post here:

Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Illinois, Chicago - Video

Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study …

(PRWEB) December 30, 2014

Psoriasis: Targets and Therapy has published the original research Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: An ethnography study.

As corresponding author Mr Siva Narayanan says Our ethnography study is one of the first of its kind in the Psoriasis arena to uncover and describe subtle or less well-defined HRQoL concepts and highlight the voice of the patient and their perception of their disease. As such, we were able to highlight the issues such as patients self-isolation, relationships with their partner and family, self-consciousness and anxiety, and the extensive planning and daily routines that are required to cope with everyday life and avoid uncomfortable social situations. We also exposed cultural differences in this study, including differing expression of emotional impacts and (un)willingness/(in)ability to discuss psoriasis with others, which contributes to severe psychosocial burden.

Mr Narayanan continues We believe that the findings from our study could aid families, care givers and healthcare providers alike in recognizing the psoriasis disease burden (from patient perspective) and accordingly suggest coping techniques to improve patient HRQoL. Further, our results could inform development and/or refining of PRO instruments in psoriasis.

As Dr Uwe Wollina, Editor-in-Chief, explains There are very few investigations on psoriasis available. This paper tries to bridge this gap of knowledge.

Psoriasis: Targets and Therapy is an international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life.

Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.

Excerpt from:

Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study ...

The Wall Street Journal: Novartis psoriasis drug approved in Japan

The Novartis headquarters in Basel, Switzerland.

ZURICH--Swiss pharmaceutical company Novartis AG said Friday that it won approval in Japan for a new psoriasis drug, the first country to give the treatment a green light for commercialization.

Novartis NOVN, -1.28% said secukinumab, marketed as Cosentyx, is approved in the country to treat psoriasis vulgaris and psoriatic arthritis in patients who dont respond to other medication.

The drug is seen by some analysts as a potential blockbuster, industry jargon for medicines that generate more than $1 billion in sales annually. Demand for new treatments for psoriasis and related diseases is high.

Psoriasis is a chronic disease that is characterized by thick and extensive skin lesions. It causes itching, scaling and pain. Psoriatic arthritis causes joint pain, stiffness and irreversible joint damage.

Cosentyx inhibits the action of a protein found in high concentrations in skin affected by psoriasis, Novartis said.

An expanded version of this report appears at WSJ.com.

More:

The Wall Street Journal: Novartis psoriasis drug approved in Japan

Novartis Psoriasis Drug Approved In Japan

Swiss pharmaceutical giant Novartis AG (NVS: Quote) said Friday that Cosentyx has been approved in Japan for both psoriasis vulgaris and psoriatic arthritis, marking the first country approval for Cosentyx in the world. The approval also makes Cosentyx the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.

Novartis said that the Japanese Ministry of Health, Labour and Welfare approved Cosentyx or secukinumab, formerly known as AIN457, for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies.

David Epstein, Division Head, Novartis Pharmaceuticals said, "We are pleased that Japan is the first country to approve Cosentyx for both psoriasis and psoriatic arthritis, providing an alternative treatment option for more than 400,000 Japanese citizens who are living with psoriasis, and those also living with psoriatic arthritis."

Psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions, called plaques. The plaques are known to cause itching, scaling and pain, and is associated with significant impairment of physical and psychological quality of life.

Closely linked with psoriasis, PsA causes joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis and irreversible joint damage. Psoriatic arthritis affects 30 percent of psoriasis patients globally and can cause irreversible joint damage.

Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA.

Novartis noted that many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these diseases. The company noted that with today's approval, these patients now have a new treatment option that effectively treats both diseases.

The Japanese approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies, which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

It was also supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA. In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events between Cosentyx treatment arms of 300 mg and 150 mg.

Novartis obtained a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP in November 2014, recommending Cosentyx as a first-line treatment of moderate-to-severe psoriasis patients in Europe.

View original post here:

Novartis Psoriasis Drug Approved In Japan

Itchy Japan first to approve Novartis psoriasis drug

GENEVA Swiss pharmaceutical giant Novartis said Friday it has won approval to market its Cosentyx psoriasis treatment in Japan, making it the first country to authorize commercialization of the drug.

The Japanese decision allows Novartis to sell secukinumab, sold under the name Cosentyx, to adult patients suffering psoriasis vulgaris and psoriatic arthritis, and who arent responding to other medication.

The drug is considered by experts to have potentially enormous market value of between $1 billion and $2.5 billion annually. Its estimated 3 percent of the worlds population or over 125 million people suffer from some form of psoriasis, including over 400,000 in Japan alone.

Psoriasis vulgaris is a skin disease provoking thick, itchy lesions, while the articular variant causes stiffness and pain in joints.

Novartis said in a statement that during clinical testing of the drug, 70 percent of patients experienced improvement or complete clearing of their psoriasis symptoms.

Approval in Japan follows the recommendation by European drug regulators in November that Cosentyx be approved for sale as a first-line treatment for psoriasis.

Similarly, the U.S. Food and Drug Administration is expected to approve the medication in early 2015 after its panel issued a similarly positive recommendation in October.

Novartis says Cosentyx is a human monoclonal antibody that neutralizes a protein that is present in highly concentrated levels in psoriasis patients.

View post:

Itchy Japan first to approve Novartis psoriasis drug

Novartis Drug Cosentyx Approved In Japan For Psoriasis And Psoriatic Arthritis

By RTT News, December 26, 2014, 07:22:00 AM EDT

(RTTNews.com) - Swiss pharmaceutical giant Novartis AG ( NVS ) said Friday that Cosentyx has been approved in Japan for both psoriasis vulgaris and psoriatic arthritis, marking the first country approval for Cosentyx in the world. The approval also makes Cosentyx the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.

Novartis said that the Japanese Ministry of Health, Labour and Welfare approved Cosentyx or secukinumab, formerly known as AIN457, for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies.

David Epstein, Division Head, Novartis Pharmaceuticals said, "We are pleased that Japan is the first country to approve Cosentyx for both psoriasis and psoriatic arthritis, providing an alternative treatment option for more than 400,000 Japanese citizens who are living with psoriasis, and those also living with psoriatic arthritis."

Psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions, called plaques. The plaques are known to cause itching, scaling and pain, and is associated with significant impairment of physical and psychological quality of life.

Closely linked with psoriasis, PsA causes joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis and irreversible joint damage. Psoriatic arthritis affects 30 percent of psoriasis patients globally and can cause irreversible joint damage.

Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA.

Novartis noted that many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these diseases. The company noted that with today's approval, these patients now have a new treatment option that effectively treats both diseases.

The Japanese approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies, which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

It was also supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA. In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events between Cosentyx treatment arms of 300 mg and 150 mg.

Read the original:

Novartis Drug Cosentyx Approved In Japan For Psoriasis And Psoriatic Arthritis

Novartis'' Cosentyx Approved In Japan For Both Psoriasis And Psoriatic Arthritis

By RTT News, December 26, 2014, 02:39:00 AM EDT

(RTTNews.com) - Novartis ( NVS ) said Friday that the Japanese Ministry of Health, Labour and Welfare or MHLW approved Cosentyx (secukinumab, formerly known as AIN457), for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies (except for biologics).

The company noted that the approval marks the first country approval for Cosentyx in the world and makes it the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.

The approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis and supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA.

In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events or AEs between Cosentyx treatment arms (300 mg and 150 mg).

Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA. As approximately 30% of psoriasis patients are also affected by PsA globally.

Psoriatic arthritis is a debilitating, long-lasting inflammatory disease linked with significant disability, poor quality of life and reduced life expectancy.

The company said that the US Food and Drug Administration approval in the same indication is anticipated in early 2015 following the unanimous recommendation of approval in October 2014 from the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US FDA.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read more from the original source:

Novartis'' Cosentyx Approved In Japan For Both Psoriasis And Psoriatic Arthritis